The estimated Net Worth of Karen A Dawes is at least $24.8 Million dollars as of 14 June 2024. Ms. Dawes owns over 2,953 units of Repligen stock worth over $12,643,578 and over the last 21 years she sold RGEN stock worth over $11,787,868. In addition, she makes $331,284 as Independent Chairperson of the Board at Repligen.
Karen has made over 29 trades of the Repligen stock since 2005, according to the Form 4 filled with the SEC. Most recently she exercised 2,953 units of RGEN stock worth $199,948 on 14 June 2024.
The largest trade she's ever made was exercising 20,000 units of Repligen stock on 20 April 2020 worth over $66,000. On average, Karen trades about 3,453 units every 107 days since 2003. As of 14 June 2024 she still owns at least 88,170 units of Repligen stock.
You can see the complete history of Ms. Dawes stock trades at the bottom of the page.
Karen A. Dawes serves as Independent Chairperson of the Board of the Company. She is currently President of Knowledgeable Decisions, LLC, a management consulting firm. Ms. Dawes served from 1999 to 2003 as Senior Vice President and U.S. Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals Group. Prior to joining Bayer, she was Senior Vice President, Global Strategic Marketing, at Wyeth LLC (“Wyeth”), a pharmaceutical company (formerly known as American Home Products), where she held responsibility for worldwide strategic marketing. Ms. Dawes also served as Vice President, Commercial Operations for Genetics Institute, Inc., which was acquired by Wyeth in January 1997, designing and implementing that company’s initial commercialization strategy to launch BeneFIX® and Neumega®. Ms. Dawes began her pharmaceuticals industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of marketing positions, serving most recently as Vice President, Marketing of the Pratt Division. At Pfizer, she directed launches of Glucotrol®/Glucotrol XL®, Zoloft®, and Cardura®. Ms. Dawes also serves on the board of directors of two publicly traded companies: Assertio Therapeutics, Inc. and Medicenna Therapeutics Corp, and on one not-for-profit company, Medicines360. Ms. Dawes received a B.A. and M.A. in English from Simmons College and an M.B.A. from Harvard University Graduate School of Business. Ms. Dawes’ qualifications to sit on the Company’s Board of Directors include her extensive strategic experience in both a managerial and consulting capacity with pharmaceutical companies as well as her considerable commercial background.
As the Independent Chairperson of the Board of Repligen, the total compensation of Karen Dawes at Repligen is $331,284. There are 6 executives at Repligen getting paid more, with Anthony Hunt having the highest compensation of $4,424,560.
Karen Dawes is 68, she's been the Independent Chairperson of the Board of Repligen since 2011. There are 1 older and 10 younger executives at Repligen. The oldest executive at Repligen Corp. is Thomas Ryan, 78, who is the Independent Director.
Karen's mailing address filed with the SEC is C/O REPLIGEN CORPORATION, 41 SEYON ST., BLDG 1, STE 100, WALTHAM, MA, 02453.
Over the last 21 years, insiders at Repligen have traded over $118,224,292 worth of Repligen stock and bought 160,440 units worth $1,459,521 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Glenn P Muir, and Walter C Herlihy. On average, Repligen executives and independent directors trade stock every 33 days with the average trade being worth of $3,015,702. The most recent stock trade was executed by Ralf Kuriyel on 2 August 2024, trading 7,148 units of RGEN stock currently worth $1,139,034.
repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.
Repligen executives and other stock owners filed with the SEC include: